# A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

> **NCT04123470** · PHASE1,PHASE2 · COMPLETED · sponsor: **Lokon Pharma AB** · enrollment: 24 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **GENETIC:** delolimogene mupadenorepvec
- **BIOLOGICAL:** atezolizumab

## Key facts

- **NCT ID:** NCT04123470
- **Lead sponsor:** Lokon Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-28
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04123470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04123470, "A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04123470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*